Global Blood Supply, Tissue Banking & Transplantation Industry
The global blood industry (which is a segment of the healthcare sector) refers to the collecting, testing, processing and typing of blood, reports BCC Research. It also involves the creation of blood derivatives necessary for the treatment of patients with blood problems. The medical industry is reliant on the blood supply industry to supply adequate blood to their patients, particularly in the cases of organ transplantation and surgical procedures.
Organ transplantation industry statistics show that the industry is witnessing progress regarding transplantation methods and the development of artificial organs, reports BCC Research. Development in transplantation methods is helping cut back on the rate of infection and organ rejection. Due to the small number of donors compared with the number of patients in need of organs, it is important to keep infection and rejection to a minimum, and make full use of the available organs.
Key Market Segments
The global blood market encompasses products necessary to collect, process, transfuse and type blood, along with the sale of blood therapeutics. According to BCC Research, the market reached $30 billion in 2010. The market is expected to record over 8% yearly growth to reach $45 billion in 2015. Blood therapeutics are expected to record yearly growth of almost 11% between 2010 and 2015. Common blood therapeutic products include coagulation factors, antithrombin products, immunoglobulins and albumin. This market segment was worth almost $16 billion in 2010, and is forecast to exceed $25 billion in 2015. Sales for blood typing, testing, collection and processing were close to $15 billion in 2010. This market segment is expected to record close to 6% yearly growth between 2010 and 2015 to reach $18 billion.
Regenerative medicine encompasses bioengineering for the repair of cells, organs, tissues, stem-cell biology, tissue engineering, and nanoscience. It involves the treatment of diseased or damaged human tissue by replacing it with therapeutically induced or laboratory-grown human tissue, reports RNCOS. The global regenerative medicine industry exceeded $7 billion in 2010 and is set to record a high rate of growth over coming years, fuelled by new treatments and technologies. Market growth will also be driven by an aging population and rising cases of degenerative disease.
The stem cell industry involves the replacement of damaged or diseased cells. Kalorama Information points to the importance of the industry also as a research tool, allowing scientists to explore organ function and the development of disease through in-vitro study. In the future, stem cells may be used to test emerging therapies to explore their impact on diseased cells.
GBI Research estimates the global market for transplant immunosuppressant drugs used recorded close to 7% yearly growth between 2004 and 2010. The market is expected to see just over 6% yearly growth between 2010 and 2018 to exceed $5.5 billion. Key players operating in this market include Astellas Pharma, Novartis, F. Hoffman La Roche and Genzyme Corporation.
The global organ and tissue transplant market was worth close to $55 billion in 2010, according to BCC Research. The market is expected to record in excess of 8% yearly growth through 2015 to reach $80 billion. Tissue typing and tissue products are expected to record 12% yearly growth to grow from almost $315 million in 2010 to reach almost $555 million in 2015. Tissue product development is expected to record yearly growth of almost 11% to exceed $25 billion in 2015. Alternative technologies reached almost $30 billion in 2010, and are expected to record yearly growth of almost 7% to hit $40 billion in 2015.